Latest Breaking News On - Central connecticut dermatology - Page 2 : comparemela.com

Secukinumab Rapidly Improves Disease Severity in Mild to Moderate Psoriasis

Secukinumab treatment resulted in greater improvements compared with placebo at week 12, with responses increasing through week 52.

Yale universityUnited statesBrucee stroberYale university school of medicineCentral connecticut dermatologyClinical dermatology conferenceYale university schoolGlobal assessmentPsoriasis areaSeverity index

JAK Inhibitors Are Revolutionizing Dermatology Field, Says Dr Mona Shahriari

Janus kinase (JAK) inhibitors are not only efficacious in terms of skin disease improvement, but also in terms of itch management, explained Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology.

Yale universityUnited statesMona shahriariCentral connecticut dermatologyClinical dermatology conferenceCase conversationsFall clinical dermatologyJak inhibitor

Tremfya efficacious in psoriasis in patients with skin of color

Tremfya efficacious in psoriasis in patients with skin of color
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesMona shahriariKristen dowdCentral connecticut dermatologySurface areaPsoriasis scalp severity index

Spesolimab Prevents Generalized Pustular Psoriasis Flares In Effisayiltm 2 Trial

Spesolimab Prevents Generalized Pustular Psoriasis Flares In Effisayiltm 2 Trial
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Yale universityUnited statesBruce stroberCarinne brouillonFrida dunger johnssonBoehringer ingelheimEuropean unionChina national medical products administrationDrug administrationWorld congressClinical professorCentral connecticut dermatologyExecutive directorHuman pharmaBreakthrough therapy designationDrug evaluation

Subcutaneous Spesolimab Reduces GPP Flares: Phase 2 Study

For generalized pustular psoriasis, treatment with the subcutaneously administered IL-36 receptor antagonist resulted in a significant reduction in flares compared with placebo.

South carolinaUnited statesNew havenYale universityBruce stroberTodd schlesingerEuropean unionBoehringer ingelheimDrug administrationWorld congressClinical research centerCentral connecticut dermatologyMedscape medical newsPresented july